In this study, enduring antitumor immune response is identified as a key therapeutic feature for HER2-DC1 i.t. combined with anti-HER2 antibodies treatment, supported by rejection of secondary HER2pos tumor challenge and detection of increased levels of both immune stimulatory cytokines and pro-inflammatory chemokines. This evidence concerns the gene ERBB2 and neoplasm.